These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
501 related articles for article (PubMed ID: 33994237)
1. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. Kalkowska DA; Pallansch MA; Wassilak SGF; Cochi SL; Thompson KM Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A136-A141. PubMed ID: 33994237 [TBL] [Abstract][Full Text] [Related]
2. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain. Kalkowska DA; Pallansch MA; Wilkinson A; Bandyopadhyay AS; Konopka-Anstadt JL; Burns CC; Oberste MS; Wassilak SGF; Badizadegan K; Thompson KM Risk Anal; 2021 Feb; 41(2):329-348. PubMed ID: 33174263 [TBL] [Abstract][Full Text] [Related]
3. Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation. Thompson KM; Kalkowska DA; Badizadegan K Front Public Health; 2023; 11():1098419. PubMed ID: 37033033 [TBL] [Abstract][Full Text] [Related]
4. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation. Duintjer Tebbens RJ; Hampton LM; Thompson KM BMC Infect Dis; 2016 May; 16():231. PubMed ID: 27230071 [TBL] [Abstract][Full Text] [Related]
6. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use. Duintjer Tebbens RJ; Hampton LM; Thompson KM BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198 [TBL] [Abstract][Full Text] [Related]
7. Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart. Kalkowska DA; Pallansch MA; Cochi SL; Kovacs SD; Wassilak SGF; Thompson KM Risk Anal; 2021 Feb; 41(2):320-328. PubMed ID: 32632925 [TBL] [Abstract][Full Text] [Related]
8. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. Thompson KM; Duintjer Tebbens RJ BMC Infect Dis; 2015 Sep; 15():376. PubMed ID: 26382234 [TBL] [Abstract][Full Text] [Related]
9. Outbreak response strategies with type 2-containing oral poliovirus vaccines. Kalkowska DA; Wassilak SGF; Pallansch MA; Burns CC; Wiesen E; Durry E; Badizadegan K; Thompson KM Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A142-A152. PubMed ID: 36402659 [TBL] [Abstract][Full Text] [Related]
10. Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes. Thompson KM; Duintjer Tebbens RJ J Infect Dis; 2017 Jul; 216(suppl_1):S168-S175. PubMed ID: 28838198 [TBL] [Abstract][Full Text] [Related]
11. Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017-2021. Alleman MM; Jorba J; Riziki Y; Henderson E; Mwehu A; Seakamela L; Howard W; Kadiobo Mbule A; Nsamba RN; Djawe K; Yapi MD; Mengouo MN; Gumede N; Ndoutabe M; Kfutwah AKW; Senouci K; Burns CC Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A35-A47. PubMed ID: 36907733 [TBL] [Abstract][Full Text] [Related]
12. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa. Cooper LV; Bandyopadhyay AS; Gumede N; Mach O; Mkanda P; Ndoutabé M; Okiror SO; Ramirez-Gonzalez A; Touray K; Wanyoike S; Grassly NC; Blake IM Lancet Infect Dis; 2022 Feb; 22(2):284-294. PubMed ID: 34648733 [TBL] [Abstract][Full Text] [Related]
14. Modeling the spread of circulating vaccine-derived poliovirus type 2 outbreaks and interventions: A case study of Nigeria. Sun Y; Keskinocak P; Steimle LN; Kovacs SD; Wassilak SG Vaccine X; 2024 Jun; 18():100476. PubMed ID: 38617838 [TBL] [Abstract][Full Text] [Related]
15. The risk of type 2 oral polio vaccine use in post-cessation outbreak response. McCarthy KA; Chabot-Couture G; Famulare M; Lyons HM; Mercer LD BMC Med; 2017 Oct; 15(1):175. PubMed ID: 28974220 [TBL] [Abstract][Full Text] [Related]
16. Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences. Kalkowska DA; Wassilak SGF; Wiesen E; Burns CC; Pallansch MA; Badizadegan K; Thompson KM Risk Anal; 2024 Feb; 44(2):366-378. PubMed ID: 37344934 [TBL] [Abstract][Full Text] [Related]
17. Assessing country compliance with circulating vaccine-derived poliovirus type 2 outbreak response standard operating procedures: April 2016 to December 2020. Darwar R; Biya O; Greene SA; Jorba J; Al Safadi M; Franka R; Wiesen E; Durry E; Pallansch MA Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A25-A34. PubMed ID: 36863925 [TBL] [Abstract][Full Text] [Related]
18. [Advances in researches of serotype 2 novel oral polio vaccine]. Chen SY; Li Y; Yang JS; Yin XX Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Mar; 55(3):413-417. PubMed ID: 33730837 [TBL] [Abstract][Full Text] [Related]
19. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM BMC Infect Dis; 2016 Mar; 16():137. PubMed ID: 27009272 [TBL] [Abstract][Full Text] [Related]
20. Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic. Molodecky NA; Jafari H; Safdar RM; Ahmed JA; Mahamud A; Bandyopadhyay AS; Shukla H; Quddus A; Zaffran M; Sutter RW; Grassly NC; Blake IM Vaccine; 2023 Apr; 41 Suppl 1():A93-A104. PubMed ID: 34629206 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]